liposomal curcumin

ApprovedSmall molecule

SSignPath Pharma, Inc.

liposomal curcumin is one of 52 small molecule programs targeting Hysterectomy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HysterectomyActive, not recruiting

Multiple MyelomaActive, not recruiting

HysterectomyApproved

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

liposomal curcumin

SSignPath Pharma, Inc.

Approved

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Abecma

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Multiple Myeloma

NCT07456605

Clinical

Trials by Indication[1]

Lip1 trial

Evaluation of Liposomal Curcumin in Healthy Volunteers

Completed·SSignPath Pharma, Inc.·Phase 1·NCT01403545·50 enrolled

Hysterectomy1 trial

Effectiveness of Curcuminoids in Controlling Postoperative Pain Following Total Laparoscopic Hysterectomy

Not yet recruiting·EErzincan Military Hospital·Phase 4·NCT06886035·126 enrolled

Hemodialysis1 trial

High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.

Completed·UUniversity of Florida·Phase 3·NCT06381076·35 enrolled

Multiple Myeloma1 trial

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

Not yet recruiting·UUniversity Health Network, Toronto·Phase 1·NCT07456605·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for liposomal curcumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — liposomal curcumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for liposomal curcumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SignPath Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSignPath Pharma, Inc.

liposomal curcumin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Lip1 trial

Hysterectomy1 trial

Hemodialysis1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News